Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.652
Neutral
RSI(14)
46.741
Neutral
STOCH(KDJ)(9,3,3)
50.918
Buy
ATR(14)
2.858
Low Volatility
CCI(14)
36.985
Neutral
Williams %R
40.568
Buy
TRIX(12,20)
-0.243
Sell
StochRSI(14)
100.000
Overbought
Cardinal Health Inc
CAH151.100USD
+0.540+0.36%
Market hours （ET）Quotes delayed by 15 min
36.11BMarket Cap
23.13P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Currency: USD Updated：2025-09-03Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
18
analysts
Buy
Current Rating
181.222
Target Price
+21.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. The Company’s segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
Industry Leader
The company's revenue leads the industry, with the latest annual revenue totaling USD 226.83B.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 25.09% year-on-year.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 31.52%.
Fairly Valued
The company’s latest is 23.24, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 214.25M shares, decreasing 4.16% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 30.47M shares of this stock.
Financial Health
Currency: USD Updated：2025-09-03The company's current financial score is 9.21, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 54.88B, representing a year-over-year increase of 0.02%, while its net profit experienced a year-over-year increase of 93.87%.
Score
Financials
8.33
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
10.00
Operational Efficiency
8.08
Growth Potential
10.00
Shareholder Returns
9.64
Company Valuation
Currency: USD Updated：2025-09-03The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is 23.04, which is 75.87% below the recent high of 40.52 and -0.20% above the recent low of 23.09.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 16/689
No Data
Earnings Forecast
Currency: USD Updated：2025-09-03The company’s current earnings forecast score is 8.11, which is higher than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Cardinal Health Inc is 184.00, with a high of 203.00 and a low of 152.11.
Score
Support & Resistance
No Data
Analyst Rating
Based on
18
analysts
Buy
Current Rating
181.222
Target Price
+21.18%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
178
Total
5
Median
8
Average
Company name
Ratings
Analysts
Cardinal Health Inc
CAH
18
Biogen Inc
BIIB
36
Amgen Inc
AMGN
34
Vertex Pharmaceuticals Inc
VRTX
33
Alnylam Pharmaceuticals Inc
ALNY
33
Eli Lilly and Co
LLY
31
1
2
3
...
36
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated：2025-09-03The company’s current price momentum score is 8.96, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 160.00 and the support level at 138.11, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
149.528
Buy
MA10
149.379
Buy
MA20
150.593
Buy
MA50
156.856
Sell
MA100
152.921
Sell
MA200
139.146
Buy
Institutional Confidence
Currency: USD Updated：2025-09-03The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 89.77%, representing a quarter-over-quarter increase of 0.06%. The largest institutional shareholder is The Vanguard, holding a total of 30.47M shares, representing 12.76% of shares outstanding, with 0.70% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
State Street Global Advisors (US)
Geode Capital Management, L.L.C.
Fidelity Management & Research Company LLC
BlackRock Financial Management, Inc.
Norges Bank Investment Management (NBIM)
BlackRock Investment Management, LLC
BlackRock Asset Management Ireland Limited
1
2
Risk Assessment
Currency: USD Updated：2025-09-03The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 6.54, which is higher than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 0.74. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.72
VaR
+2.15%
240-Day Maximum Drawdown
+13.07%
240-Day Volatility
+28.18%
Return
Best Daily Return
60 days
+4.55%
120 days
+4.55%
5 years
+7.01%
Worst Daily Return
60 days
-7.21%
120 days
-7.21%
5 years
-14.26%
Sharpe Ratio
60 days
-0.27
120 days
+1.76
5 years
+1.13
Risk Assessment
Maximum Drawdown
240 days
+13.07%
3 years
+18.92%
5 years
+26.65%
Return-to-Drawdown Ratio
240 days
+2.70
3 years
+1.99
5 years
+1.41
Skewness
240 days
-0.39
3 years
-0.17
5 years
-0.76
Volatility
Realised Volatility
240 days
+28.18%
5 years
+26.40%
Standardised True Range
240 days
+1.93%
5 years
+1.23%
Downside Risk-Adjusted Return
120 days
+201.77%
240 days
+201.77%
Maximum Daily Upside Volatility
60 days
+19.43%
Maximum Daily Downside Volatility
60 days
+27.48%
Liquidity
Average Turnover Rate
60 days
+0.98%
120 days
+1.01%
5 years
--
Turnover Deviation
20 days
+25.59%
60 days
+6.92%
120 days
+9.96%
Peer Comparison
Currency: USD Updated：2025-09-03Cardinal Health Inc
CAH
7.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
7.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
7.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stoke Therapeutics Inc
STOK
7.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
7.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
7.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
